Granted Patent
B2
US 12,458,608 · App. 17/421,308 · Granted Nov 4, 2025
N-Acetylcysteine Amide (NACA) and (2R,2R′)-3,3′ disulfanediyl BIS(2-acetamidopropanamide) (DINACA) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvement
Assignee:
NACUITY PHARMACEUTICALS, INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention includes a method for the use of N-acetylcysteine (NAC), N-acetylcysteine amide (NAC A) or (2R,2R′)-3,3′-disulfanediylbis(2-acetamidopropanamide) (diNACA) for the prevention and treatment of radiation dermatitis, radiation damage to the skin, xeroderma pigmentosa or protect patients with xeroderma pigmentosa from skin damage caused by exposure to the sun or other radiation, bioweapons, chemical burns, heat burns, contact damage caused by friction, contact dermatitis, hypersensitivity reactions and skin wrinkles and dehydration, skin lightening, skin whitening, and/or skin improvement in a human that comprises administering to the human a therapeutically effective amount of NAC, NACA or diNACA.
Claims (20)
1 . A method for use of (2R,2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide) (diNACA) to reduce melanocyte activity in a human subject that comprises:
identifying a human patient in need of skin lightening or whitening; and
administering to the human patient a therapeutically effective amount of diNACA sufficient to reduce melanocyte activity.
2 . The method of claim 1 , wherein the diNACA is provided in or with a pharmaceutically acceptable carrier.
3 . The method of claim 1 , wherein the diNACA is administered orally, intravenously, intramuscularly, intranasally, enterally, intraocularly, subretinally, intravitreally, topically, ocularly, sublingually, cutaneously, subcutaneously, or rectally.
4 . The method of claim 1 , wherein the diNACA is administered in daily doses of about 0.5 to 150 mg/Kg.
5 . The method of claim 1 , wherein the diNACA is administered two or three times daily.
6 . The method of claim 1 , wherein the diNACA is administered with a second active agent.
7 . The method of claim 1 , wherein the diNACA is administered with a second active agent selected from at least one of ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, α-tocopherol, citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, or phosphoric acid.
8 . The method of claim 1 , wherein the dose for administration is 100, 150, 300, 333, 400, 500, 600, 700, 750, 800, 900, 1,000, 2,500, 5,000, 7,500, or 10,000 mg per dose.
9 . The method of claim 1 , wherein the diNACA is delivered orally via a mini-tablet, capsule, tablet, effervescent, dual release, mixed release, sachet, powder, or liquid.
10 . The method of claim 1 , wherein a therapeutically effective amount of 100, 150, 300, 333, 400, 500, 600, 700, 750, 800, 900, 1,000, 2,500, 5,000, 7,500, or 10,000 mg decreases at least one of the loss of night vision, the loss of overall visual acuity, the loss of visual field, by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or more as compared to an untreated control subject over a defined period of time, selected from at least one of 2 weeks, one month, 2 months, 3 months, 6 months, one year, 2 years, or 5 years.
11 . A method for use of (2R,2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide) (diNACA) for at least one of: skin lightening or whitening, in a human subject that comprises:
administering to the human patient a therapeutically effective amount of diNACA.
12 . The method of claim 11 , wherein the diNACA is provided in or with a pharmaceutically acceptable carrier.
13 . The method of claim 11 , wherein the diNACA is administered orally, intravenously, intranasally, intramuscularly, enterally, intraocularly, subretinally, intravitreally, topically, ocularly, sublingually, cutaneously, subcutaneously, or rectally.
14 . The method of claim 11 , wherein the diNACA is administered in daily doses of about 0.5 to 150 mg/Kg.
15 . The method of claim 4 , wherein the diNACA is administered two or three times daily.
16 . The method of claim 11 , wherein the diNACA is administered with a second active agent.
17 . The method of claim 11 , wherein the dose for administration is 100, 150, 300, 333, 400, 500, 600, 700, 750, 800, 900, 1,000, 2,500, 5,000, 7,500, or 10,000 mg per dose.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 21, 2021
From: WALL, G. MICHAEL
To: NACUITY PHARMACEUTICALS, INC.
Reel/Frame 057543/0032 →
Continuity (2)
Provisional Application
62791422
· Jan 11, 2019
References Cited (175)
US 3340147A
· Martin
· 1967
[cited by applicant]
US 5874468A
· Atlas
· 1999
[cited by applicant]
US 6420429B1
· Atlas
· 2002
[cited by applicant]
US 8354449B2
· Goldstein
· 2013
[cited by applicant]
US 8937099B2
· Goldstein
· 2015
[cited by applicant]
US 8993627B2
· Goldstein
· 2015
[cited by applicant]
US 9216162B2
· Goldstein
· 2015
[cited by applicant]
US 9763902B2
· Warner
· 2017
[cited by applicant]
US 9889103B2
· Warner
· 2018
[cited by applicant]
US 20030027745A1
· Repine
· 2003
[cited by applicant]
US 20030229141A1
· Yu
· 2003
[cited by examiner]
US 20090234011A1
· Goldstein
· 2009
[cited by applicant]
US 20120142550A1
· Zehnder et al.
· 2012
[cited by applicant]
US 20120150029A1
· Debuc
· 2012
[cited by applicant]
US 20130303436A1
· Wilson
· 2013
[cited by applicant]
US 20190135741A1
· Wall
· 2019
[cited by applicant]
US 20200281944A1
· Piraee
· 2020
[cited by applicant]
CA 3078680A1
· 2019
[cited by applicant]
CA 3079196C
· 2021
[cited by applicant]
CN 108618993A
· 2018
[cited by applicant]
EP 1975621A1
· 2008
[cited by applicant]
GB 1114369A
· 1968
[cited by applicant]
JP 2005350405A
· 2005
[cited by applicant]
JP 2008538586A5
· 2008
[cited by applicant]
JP 2013533234A
· 2013
[cited by applicant]
JP 202023549
· 2020
[cited by applicant]
WO 2003016527
· 2003
[cited by applicant]
WO 2004012652A3
· 2004
[cited by applicant]
WO 2004028536A1
· 2004
[cited by applicant]
WO WO2006116353A2
· 2006
[cited by examiner]
WO 2010048716A1
· 2010
[cited by applicant]
WO WO2011044230A2
· 2011
[cited by examiner]
WO 2013138744A1
· 2013
[cited by applicant]
WO 2014100361A1
· 2014
[cited by applicant]
WO 2015148880A1
· 2015
[cited by applicant]
WO 2016073829A2
· 2016
[cited by applicant]
WO 2017161318A1
· 2017
[cited by applicant]
WO 2019060623A1
· 2019
[cited by applicant]
WO 2019060634A1
· 2019
[cited by applicant]
WO 2019060704A1
· 2019
[cited by applicant]
WO 2019094383A1
· 2019
[cited by applicant]
WO 2019097434A1
· 2019
[cited by applicant]
WO 2020102810A1
· 2020
[cited by applicant]
WO 2020146660A1
· 2020
[cited by applicant]
WO 2020146666
· 2020
[cited by applicant]
WO 2020146674A1
· 2020
[cited by applicant]
Maddirala, et al. “Prevention and reversal of selenite-induced cataracts by N-acetylcysteine amide in Wistar rats” BMC Ophthalmology (2017) 17:54.
[cited by applicant]
Maeda, et al., “Important Role of the 3-Mercaptopropionamide Moiety in Glutathione: Promoting Effect on Decomposition of the Adduct of Glutathione with the Oxoammonium Ion of TEMPO”, J Organic Chem (2005). 70:8338-8343.
[cited by applicant]
Martin, Tellis, “Amides of N-Acylcysteines as Mucolytic Agents”, J Med Chem (1967), 10:1172-1176.
[cited by applicant]
McMenamim, et al., Simultaneous analysis of multiple aminothiols in human plasma by high performance liquid chromatography with fluorescence detection, J Chrom B, 877 (2009) 3274-3281.
[cited by applicant]
Miller, WF. “Aerosol therapy in acute and chronic respiratory disease.” Arch Intern Med 1973;131:148-155.
[cited by applicant]
Monostori, et al., Determination of glutathione and glutathione disulfide in biological samples: an in-depth review. J Chrom B, 877 (2009) 3331-3346.
[cited by applicant]
Moore, et al., A new LC-MS/MS method for the clinical determination of reduced and oxidized glutathione from whole blood. J Chrom B, 929 (2013) 51-55.
[cited by applicant]
Nakagami, et al. “A novel Nrf2 activator from microbial transformation inhibits radiation-induced dermatitis in mice,” Journal of Radiation Research, vol. 57, No. 5, 2016, pp. 567-571.
[cited by applicant]
Zhang, et al., “Effects of N-acetylcysteine and glutathione ethyl ester drops on streptozotocin-induced diabetic cataract in rats.” Mol Vis. 2008;14:862-70.
[cited by applicant]
Nash, et al., “Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis.” Cochrane Database Syst Rev 2009;(1):CD007168.
[cited by applicant]
New, et al., Evaluation of BEH C18, BEH HILIC, and HSS T3 (C18) Column Chemistries for the UPLC-MS-MS Analysis of Glutathione, Glutathione Disulfide, and Ophthalmic Acid in Mouse Liver and Human Plasma. J Chrom Sci, 46 …
[cited by applicant]
Niemeyer, Selective Rod-and Cone-ERG Responses on Retinal Degenerations, Digital Journal of Ophthalmology, 1998, vol. 4, No. 10, 1998.
[cited by applicant]
Nozal, et al., Determination of glutathione, cysteine, and N-acetylcysteine in rabbit eye tissues using high-performance liquid chromatography and post-column derivatization with 5,5′-dithiobis(2-nitrobenzoic acid). J C…
[cited by applicant]
Park, et al.: “Targeted and Reversible Blood-Retinal Barrier Disruption via Focused Ultrasound and Microbubbles” PLoS One (2012), 7(8):e42754.
[cited by applicant]
Poole, et al., “Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease.” Cochrane Database Syst Rev 2015;(7):CD001287).
[cited by applicant]
Reyes, et al., Neuronal glutathione content and antioxidant capacity can be normalized in situ by N-acetyl cysteine concentrations attained in human cerebrospinal fluid, Neurotherapeutics, 13 (2016) 217-225.
[cited by applicant]
Rubin BK. Aerosol Medications for Treatment of Mucus Clearance Disorders Respiratory care 2015; 60(6): 825-832.
[cited by applicant]
Šalamon, et al., “Medical and Dietary Uses of N-Acetylcysteine.” Antioxidants 2019, 8, 111.
[cited by applicant]
Schimel, et al., “N-Acetylcysteine Amide (NACA) Prevents Retinal Degeneration by Up-Regulating Reduced Glutathione Production and Reversing Lipid Peroxidation.” The American Journal of Pathology, (2011), 178(5):2032-204…
[cited by applicant]
Sekhon, “Exploiting the Poer of Stereochemistry in Drugs . . . ”, Journal of Modern Medicinal Chemistry, 2013, 10-36.
[cited by applicant]
Shen, et al., “Oxidative damage is a potential cause of cone cell death in retinitis pigmentosa.” J Cell Physiol, (2005), 203(3):457-64.
[cited by applicant]
Shintani, et al., “Review and Update: Current treatment trends for Patients with Retinitis Pigmentosa,” Optometry (2009), 80:384-401.
[cited by applicant]
Squellerio, et al., Direct glutathione quantification in human blood by LC-MS/MS: comparison with HPLC with electrochemical detection. J Pharm Biomed Anal, 71 (2012) 111-8.
[cited by applicant]
Stey, et al., “The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review.” Eur Respir J. 2000; 16(2):253-62.
[cited by applicant]
Suh, et al., Clinical assay of four thiol amino acid redox couples by LC-MS/MS: utility in thalassemia, J Chrom B, 877 (2009) 3418-3427.
[cited by applicant]
Sunitha, et al., N-acetylcysteine amide: a derivative to fulfull the promises of N-acetylcysteine. Free Radic Res, 47 (2013) 357-367.
[cited by applicant]
Tam, et al., “Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis.” Cochrane Database Syst Rev 2013;(7):CD007168.
[cited by applicant]
Tarrant et al. “Mucoactive agents for adults with acute lung conditions: A systematic review.” Heart & Lung (2019) 48(2):141-147.
[cited by applicant]
Tobwala et al. “N-acetylcysteine Amide (NACA), a Novel GSH Prodrug: Its Metabolism and Implications in Health”, abrou, 2013, Capter VI. ISBN:978-1-62417-460-5.
[cited by applicant]
Tse, et al., “High-dose N-acetylcysteinine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study.” Chest, (2013). 144(1):106-118.
[cited by applicant]
Tuson, et al., “Overexpression of CERKL, a gene responsible for retinitis pigmentosa in humans, protects cells from apoptosis induced by oxidative stress.” Mol Vis. (2009), 15:168-80.
[cited by applicant]
United States Patent & Trademark Office (ISA) International Search Report and Written Opinion PCT/US2015/059589 Dated Feb. 2, 2016, 10 pg.
[cited by applicant]
Usui, et al., “Increased expression of catalase and superoxide dismutase 2 reduces cone cell death in retinitis pigmentosa.” Mol Ther J Am Soc Gene Ther. (2009), 17(5):778-86.
[cited by applicant]
Usui, et al., “NADPH oxidase plays a central role in cone cell death in retinitis pigmentosa.” J Neurochem. (2009), 110(3):1028-37.
[cited by applicant]
Wang, et al., “Relationship of protein-glutathione mixed disulfide and thioltransferase in H2O2-induced cataract in cultured pig lens.” Exp Eye Res. May 1997;64(5):693-700.
[cited by applicant]
Wang, et al., “Hyperoxia-induced lens damage in rabbit: protective effects of N-acetylcysteine.” Mol Vis. 2009;15:2945-52.
[cited by applicant]
Weng, Bioanalytical liquid chromatography tandem mass spectrometry methods on underivatized silica columns with aqueous/organic mobile phases. J Chrom B, 796 (2003) 209-224.
[cited by applicant]
Wu, et al., “Effects of N-acetylcysteine amide (NACA, a thiol antioxidant on radiation-induced cytotoxicity in Chenese hamster ovary cells,” Life Sciences (2008), 82:1122-1130.
[cited by applicant]
Wu, et al., Separation and quantification of N-acetyl-L-cysteine and N-acetyl cysteine-amide by HPLC with fluorescence detection. Biomed Chromatogr, 20 (2006) 415-422.
[cited by applicant]
Yu, et al., “Intraretinal oxygen levels before and after photoreceptor loss in the RCS rat.” Invest Ophthalmol Vis Sci, (2000), 41(12):3999-4006.
[cited by applicant]
Ehre, et al. An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive Diseases. Am J Respir Crit Care Med. Jan. 15, 2019;199(2):171-180. doi: 10.1164/rccm.201802-02450C.
[cited by applicant]
European Patent Office, Extended European Search Report for EP 15857309.7 dated May 23, 2018.
[cited by applicant]
Han, et al., “Efficacy of nebulized acetylcysteine for relieving symptoms and reducing usage of expectorants in patients with radiation pneumonitis.” Thoracic Cancer 2018; 1-6. doi: 10.1111/1759-7714.12938.
[cited by applicant]
Kelly, “Clinical applications of N-acetylcysteine.” Altern Med Rev J Clin Ther. (1998), 3(2):114-27.
[cited by applicant]
Amer, et al., “N-acetylcysteine amide (AD4) attenuates oxidative stress in beta-thalassemia blood cells.” Biochimica et Biophysica Acta 1780 (2008) 249-255.
[cited by applicant]
Ates, et al., “Antioxidant and free radical scavenging properties of N-acetylcysteine amide (NACA) and comparison with N-acetylcysteine (NAC).” Free Radic Res. (2008), 42(4):372-7.
[cited by applicant]
Australian Patent Office (ISA), International Search Report and Written Opinion PCT/US2018/059446 dated Dec. 31, 2018, 15 pg.
[cited by applicant]
Australian Patent Office (ISA), International Search Report and Written Opinion PCT/US2018/061357 dated Dec. 18, 2018, 11 pg.
[cited by applicant]
Australian Patent Office (ISA), International Search Report and Written Opinion PCT/US2020/012968 dated Mar. 13, 2020, 10 pp.
[cited by applicant]
Australian Patent Office (ISA), International Search Report and Written Opinion PCT/US2020/012975 dated Mar. 13, 2020, 12 pp.
[cited by applicant]
Australian Patent Office (ISA), International Search Report and Written Opinion PCT/US2020/012983 dated Mar. 13, 2020, 15 pp.
[cited by applicant]
Australian Patent Office, International Search Report and Written Opinion PCT/US2021/014819 dated Mar. 25, 2021, 18 pp.
[cited by applicant]
Babizhayev, et al., Revival of the Lens Transparency with N-Acetylcarnosine.: Current Drug Therapy, 2006:1; 91-116.
[cited by applicant]
Bahat-Stroomza, et al., A novel thiol antioxidant that crosses the blood brain barrier protects dopaminergic neurons in experimental models of Parkinson's disease. European Journal of Neuroscience, 2005; 21: 637-646.
[cited by applicant]
Banerjee, et al., “HIV proteins (gp120 and Tat) and methamphetamine in oxidative stress-induced damage in the brain: Potential role of the thiol antioxidant N-acetylcysteine amide.” Free Radic Biol Med. May 15, 2010; 48…
[cited by applicant]
Betterridge, What is Oxidative Stress Metabolism, vol. 49, No. 2, Feb. 2000, pp. 3-8.
[cited by applicant]
Boone “The K-Zone: Biophysical Data Tables”, 1994-2006, downloaded from www.kevinboone.com on Mar. 14, 2009.
[cited by applicant]
Buss, et al., “Protein carbonyl measurement by a sensitive ELISA method.” Free Radic Biol Med, (1997), 23(3):361-6.
[cited by applicant]
Campochiaro, et al., “Oral N-acetylcysteine improves cone function in retinitis pigmentosa patients in phase I trial.” J Clin Invest. 2020 130(3):1527-1541.
[cited by applicant]
Carey, et al., “In vivo inhibition of I-buthionine-(S, R)-sulfoximine-induced cataracts by a novel antioxidant, N-acetylcysteine amide.” Free Radical Biol Med. 2011;15.
[cited by applicant]
Carey, et al. “N-acetyl-L-cysteine amide protects retinal pigment epithelium against methamphetamine-induced oxidative stress” Journal of Biophysical Chemistry, vol. 3, No. 2, 101-110 (2012).
[cited by applicant]
Carroll, et al., “Simultaneous quantitation of oxidized and reduced glutathione via LC-MS/MS: An insight into the redox state of hematopoietic stem cells.” Free Radical Biology and Medicine, 97 (2016) 85-94.
[cited by applicant]
Chastain, et al. “Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye.” Exp Eye Res (2016), 145:58-67.
[cited by applicant]
Davies, et al., “Measurements of protein carbonyls, ortho- and meta-tyrosine and oxidative phosphorylation complex activity in mitochondria from young and old rats.” Free Radic Biol Med, (2001), 31(2):181-90.
[cited by applicant]
Devries, et al. “N-acetyl-l-cysteine.” J Cell Biochem Suppl (1993), 17F:270-277.
[cited by applicant]
Dietzsch, et al., “Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride).” Pediatrics 1975;55:96-100.
[cited by applicant]
Dong, et al., “Compared with N-acetylcysteine (NAC), N-Acetylcysteinne Amid (NACA) Provides Increased Protein of Cone Function in a Model of Retinitis Pigmentosa.” Investigative Ophthalmology Visual Science, (2014), 55:…
[cited by applicant]
Ercal, et al., “Effects of a thiol antioxidant in various cataract models,” Acta Ophthalmologica (2016), 94:S256 (Abstract).
[cited by applicant]
Ercal, et al., High-performance liquid chromatography assay for N-acetylcysteine in biological samples following derivatization with N-(1-pyrenyl)maleimide. J Chrom B, 685 (1996) 329-334.
[cited by applicant]
European Patent Office, Extended European Search Report for EP 18876329.6 dated Oct. 29, 2019.
[cited by applicant]
European Patent Office, Extended European Search Report for EP 18882212.6 dated Jul. 6, 2021, 8 pp.
[cited by applicant]
Giustarini, et al., Pitfalls in the analysis of the physiological antioxidant glutathione (GSH) and its disulfide (GSSG) in biological samples: an elephant in the room. J Chrom B., 1019 (2016) 21-28.
[cited by applicant]
Heymann, et al., “The preparation and Some Biological Properties of the Asperagine Analog L-2@-Amino-2-carboxyethanesulfonamide,” J Am Chem Soc (1959), 81(19):5125-5128.
[cited by applicant]
Isokawa, et al., Analytical methods involving separation techniques for determination of low-molecular-weight biothiols in human plasma and blood. J Chrom B, 964 (2014) 103-115.
[cited by applicant]
Jastrzȩbska, et al., “N-acetylcysteine amide (AD4) reduces cocaine-induced reinstatement.” Psychopharmacology 2016;33:3437-3448.
[cited by applicant]
Kahns, et al., “Prodrugs as drug delivery systems. 107. Synthesis and chemical and enzymatic hydrolysis kinetics of various mono- and diester prodrug of N-acetylcysteine.” Int J Pharm (1990), 62:193-205.
[cited by applicant]
Katz, et al., Cerebrospinal fluid concentrations of N-acetylcysteine after oral administration in Parkinsons disease. Parkinsonism and Related Disorders, 21 (2015) 500-503.
[cited by applicant]
Kim, et al., “N-Acetylcysteine increases corneal cell survival in a mouse model of Fuchs endothelial corneal dystrophy,” Experimental Eye Research (2014), 127:20-25.
[cited by applicant]
Komeima, et al., “Antioxidants reduce cone cell death in a model of retinitis pigmentosa.” PNAS, (2006), 103(30):11300-11305.
[cited by applicant]
Komeina, et al., “Antioxidants slow photoreceptor cell death in mouse models of retinitis pigmentosa.” J Cell Physiol. (2007), 213(3):809-15.
[cited by applicant]
Komeina, et al., “Blockade of neuronal nitric oxide synthase reduces cone cell death in a model of retinitis pigmentosa.” Free Radic Biol Med, (2008), 45(6):905-12.
[cited by applicant]
Kusmierek, et al., Ultraviolet derivatization of low-molecular-mass thiols for high performance liquid chromatography and capillary electrophoresis analysis, J Chrom B, 879 (2011) 1290-1307.
[cited by applicant]
Grinberg, et al., “N-acetylcysteine amide, a novel cell-permeating thiol, restores cellular glutathione and protects human red blood cells from oxidative stress,” Free Radical Biol Med. (2005) ;38(1):136-145.
[cited by applicant]
Lee, et al., “N-Acetylcysteine Promotes Long-Term Survival of Cones in a Model of Retinitis Pigmentosa,” J Cell Physiol (2011), 226:1843-1849.
[cited by applicant]
Liu, et al., “A rabbit model to study biochemical damage to the lens after vitrectomy: effects of N-acetylcysteine.” Exp Eye Res. 2009;88(6):1165-70.
[cited by applicant]
Adil, et al. “N-acetylcysteine in dermatology” Indian Journal of Dermatology, Feb. 2018.
[cited by applicant]
European Patent Office, Extended European Search Report for EP 20738196.3 dated Oct. 11, 2022, 13 pp.
[cited by applicant]
Hsu, et al. “Feasibility of corneal drug delivery of cysteamine using vitamin E modified silicone hydrogel contact lenses” European Journal of Pharn1aceutics and Biopharn1aceutics 85 (2013) 531-540.
[cited by applicant]
Japan Patent Office, Notification of Reasons for Refusal dated Dec. 18, 2023 for Japanese Appl. No 2021-540019 (with english translation), 8 pp.
[cited by applicant]
Shams, et al. “Treatment of corneal cystine crystal accumulation in patients with cystinosis” Clinical Opthamalogy, Oct. 10, 2014, 2077-2078.
[cited by applicant]
Vaisbich, et al. “Oxidative Stress in Cystinosis Patients” Nephron Extra, 2011; 1:73-77, publishes online Sep. 19, 2011.
[cited by applicant]
Australian Patent Office (ISA), International Search Report and Written Opinion for PCT/US2015/060172 Dated Apr. 13, 2016, 12 pg.
[cited by applicant]
Australian Patent Office (ISA), International Search Report and Written Opinion for PCT/US2018/052065 dated Jan. 10, 2019, 10 pg.
[cited by applicant]
Australian Patent Office, International Search Report and Written Opinion PCT/US2021/036210 dated Jul. 19, 2021, 12 pp.
[cited by applicant]
Australian Patent Office, Examination Report for Australian Appl. No. 2020227015 dated Sep. 24, 2021, 6 pp.
[cited by applicant]
Bean, et al., “Comparative evaluation of antioxidant reactivity within obstructed and control rabbit urinary bladder tissue using FRAP and CUPRAC assays,” Molecular and Cellular Biochemistry (2008) 323(1-2):139-142.
[cited by applicant]
Bernardes, et al., “From Disulfide- to Thioether-Linked Glycoproteins” Angewandte Chemie, Supporting Information (2008), S1-S97.
[cited by applicant]
Canadian Patent Office, Examination Report for Canadian Patent Appl. No. 3,046,363 dated Jun. 6, 2022, 4 pp.
[cited by applicant]
Campochiaro, et al. “Is there Excess Oxidative Stress and Damage in Eyes of Patients with Retinitis Pigmentosa” Antioxidants Redox Signaling, (2015) 23(7):643-648.
[cited by applicant]
Campochiaro, et al. “The Mechanism of Cone Cell Death in Retinitis Pigmentosa”, Progress in Retinal and Eye Research (2018), 62:24-37.
[cited by applicant]
Demirel, et al. “The preventive effect of N-acetylcysteine on radiation-induced dermatitis in a rat model” Journal of BUON, 15:577-582, 2010.
[cited by applicant]
Dietz, et al., “Photochemical Reduction of 5-Bromouracil by Cysteine Derivatives and Coupling of 5-Bromouracil to Cystine Derivatives,” Photochemistry and Photobiology (1989), 49(2):121-129.
[cited by applicant]
European Patent Office, Extended European Search Report for 15770142.6 dated Oct. 20, 2017.
[cited by applicant]
European Patent Office, Extended European Search Report for 15858590.1 dated May 2, 2018.
[cited by applicant]
European Patent Office, Extended European Search Report for EP 20738980.0 dated Jan. 28, 2022, 9 pp.
[cited by applicant]
Hong, et al. “Effect of High-Dose Intravenous N-acetylcysteine on the Concentration of Plasma Sulfur-Containing Amino Acids”, The Korean Journal of Internal Medicine: 20:217-223, 2005.
[cited by applicant]
Intellectual Property India, First Examination Report for Indian Appl. No. 201917036550 dated Sep. 22, 2021, 7 pp.
[cited by applicant]
Jones, “Extracellular Redox State: Refining the Definition of Oxidative Stress in Aging,” Rejuvenation Research (2006), 9(2):169-181.
[cited by applicant]
Kunisada, et al. “CXCL1 Inhibition Regulates UVB-Induced Skin Inflammation and Tumorigenesis in Xpa-Deficient Mice” Journal of Investigative Dermatology (2017), 137, 1975-1983.
[cited by applicant]
Levine, R.L., “Carbonyl modified proteins in cellular regulation, aging, and disease” Free Radic Biol Med, 2002. 32(9): p. 790-6.
[cited by applicant]
Li, et al., “A Convenient Synthesis of Amino Acid Methyl Esters”, Molecules (2008), 13:1111-1119.
[cited by applicant]
Lu, et al., “Effects of Different Types of Oxidative Stress in RPE Cells,” J Cell Phys (2006), 206(1):119-125.
[cited by applicant]
Martinez-Fernandez De La Camara, et al., Altered Antioxidant-Oxidant Status in Aqueous Humor and Peripheral Blood of Patents with Retinitis Pigmentosa, PLOS One (2013), 8(9):E74223.
[cited by applicant]
Minozzi, et al., “An Insight into the Radical Thiol/Yne Coupling: The Emergence of Arylalkyne-tagged Suggars for te Direct Photoinduced Glycosylation of Cysteine Containing Peptides”, J. Org. Chem, 2011, 76, 450-459.
[cited by applicant]
Offen, et al. “A low molecular weight copper chelator crosses the blood-brain barrier and attentuates experimental autoimmune encephalomyelitis” Journal of Neurochemistry, 2004, 89, 1241-1251.
[cited by applicant]
Reagan-Shaw, et al. “Dose translation from animal to human studies revised” The FASEB Journal, Mar. 2007, vol. 22, (659-661).
[cited by applicant]
Riley, et al., “Glutathione in the aqueous humor of human and other species.” Investigative ophthalmology visual science, (1980), 9(1):94-96.
[cited by applicant]
Shen, et al., “Oxidative damage in age-related macular degeneration,” Histology and Histopathology (2007), 22(12):1301-1308.
[cited by applicant]
Sunitha, et al. “N-Acetylcysteine amide: a derivative to fulfill the promises of N-Aceylcysteine” Free Radical Resarch, May 2013, 47(5), 357-367.
[cited by applicant]
Supelco “Methanolic H2S04 (10./o v/v)” 1997, Sigma-Aldrich Co., 2 Pages.
[cited by applicant]
Tsai, et al. “Topical TV-Acetylcysteine Accelerates Wound Healing in Vitro and in Vivo via the PKC/Stat3 Pathway” Int. J. Mol. Sci., 2014, 15, 7563-7578.
[cited by applicant]
University of Sao Paulo, et al. “N-Acetyl Cysteine for Cystinosis Patients”, ClinicalTrials.gov [online], identifier: NCT01614431, Last update posted: Jun. 20, 2012, htps://clinicaltrials.gov/ct2/show/NCT01614431, [retr…
[cited by applicant]
Usui, et al., “Overexpression of SOD in retina: Need for increase in H202-detoxifying enzyme in same cellular compartment,” Free Radical Biology and Medicine (2011 ), 51(7):1347-1354.
[cited by applicant]